Welcome to our dedicated page for United Guardian SEC filings (Ticker: UG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United-Guardian, Inc. filings document formal disclosures for an operating company that manufactures cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. Recent 8-K reports include Item 2.02 results of operations disclosures and Regulation FD announcements tied to financial results and cash dividends.
The company’s proxy materials cover annual meeting matters, director elections, and advisory compensation votes. Its filings also provide a record of product-category performance, including disclosures related to Renacidin, cosmetic ingredient distribution, medical lubricant demand, governance actions, and shareholder meeting procedures.
United-Guardian, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected seven directors, including Ken Globus and Donna Vigilante, to serve until the next annual meeting or until successors are elected and qualified.
Stockholders approved holding future advisory votes on executive compensation every year, with 2,576,591 votes for that frequency. They also approved executive compensation on a non-binding advisory basis, with 2,562,179 votes in favor. In addition, shareholders ratified the appointment of Grassi & Co., CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 3,566,216 votes for ratification.
United-Guardian, Inc. reported stronger first‑quarter 2026 results. Net sales rose to $2,872,222, up about 16% from 2025, driven mainly by higher pharmaceutical revenue, especially Renacidin and Clorpactin, and solid growth in Lubrajel cosmetic ingredients.
Net income increased to $818,902 from $560,895, with earnings per share improving to $0.18 from $0.12. A key contributor was $303,133 of settlement income from Renacidin’s contract manufacturer following a prior facility shutdown. Operating income grew more modestly as cost of sales rose to 50% of net sales versus 45% a year earlier.
The company generated $604,536 of cash from operations and ended March 31, 2026 with $735,854 in cash and cash equivalents and $7,300,389 in marketable securities. Working capital was $10,344,756 with a current ratio of 8.1 to 1. The board declared a quarterly dividend of $0.25 per share, down from $0.35 in the prior‑year quarter. Management highlights significant customer and supplier concentrations and ongoing exposure to global trade, tariff, and supply chain risks.
United-Guardian, Inc. reported significantly improved first quarter 2026 results, with net sales rising to $2,872,222 from $2,481,127 in 2025 and net income increasing to $818,902, or $0.18 per share, from $560,895, or $0.12 per share.
Management attributed the performance mainly to stronger sales of pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose 24%, led by higher demand for Renacidin, while cosmetic ingredient sales grew 21%, supported by a 45% increase in purchases from Ashland Specialty Ingredients as it normalized inventory levels.
Other income also boosted results, including $303,133 of settlement income related to a contract manufacturer shutdown for Renacidin, alongside investment income and gains on marketable securities. The company highlighted new distribution agreements, expanded “natural” product lines, and broader Renacidin outreach as reasons to be optimistic about further sales growth in 2026.
United-Guardian, Inc. calls a virtual-only 2026 Annual Meeting for May 13, 2026 at 10:00 a.m. Eastern via Zoom for holders of common stock as of March 30, 2026. Stockholders will vote on electing seven directors, the frequency of say-on-pay votes, approving executive compensation, and ratifying Grassi & Co. as auditor for 2026.
The company has 4,594,319 common shares outstanding and a highly concentrated holder base, with Ken Globus beneficially owning 28.5% and all directors and officers together holding 29%. The Board is majority independent, with separate Audit and Compensation Committees, and has adopted insider trading and clawback policies. The proxy details 2025 compensation for President and PEO Donna Vigilante and other executives, director retainers of $54,000, and expected 2025 audit fees of about $119,000.
United-Guardian, Inc. reports 2025 net sales of $10.5M, down from $12.2M in 2024, as cosmetic ingredient revenue fell sharply, especially with its largest distributor ASI. Net income declined to $2.1M from $3.3M, with gross margin easing to 49%.
Pharmaceutical products, led by Renacidin, grew to 51% of sales and medical lubricants rose modestly, while cosmetic ingredients fell to 29%. The company generated positive operating cash flow, held $7.3M in marketable securities, carried no debt, and paid cash dividends totaling $0.60 per share in 2025.
United-Guardian, Inc. reported weaker full-year 2025 results, with net sales falling 13% to $10,545,468 from $12,181,971 in 2024. Net income declined to $2,105,738, or $0.46 per share, compared with $3,250,875, or $0.71 per share, a year earlier.
Management attributed the decline mainly to lower cosmetic ingredient sales, driven by excess inventory at its largest distributor Ashland Specialty Ingredients, softer global demand, stronger local competition in China, and tariffs. Offsetting this, pharmaceutical sales grew 15% and medical lubricants 4%, helped by higher demand in China and U.S. drug wholesalers, while Renacidin® gained access to additional drug formularies through recent approvals from two major pharmacy benefit managers.
United-Guardian, Inc. filed a current report to furnish information under Regulation FD. The company stated that on January 29, 2026 it issued a press release, which is attached to the report as Exhibit 99.1 and incorporated by reference for public disclosure.
United-Guardian director Kenneth H. Globus reported a family stock gift involving shares deemed beneficially owned by him. On January 21, 2026, 7,480 shares of United-Guardian, Inc. common stock that were owned by his wife were gifted by her to their grandson at a price of $0 per share, reflecting a non-cash transfer reported with code G. The shares are included on this Form 4 because his spouse’s holdings are treated as being beneficially owned by him.
After this transaction, the filing states that Globus’s beneficial ownership consists of 279,027 shares held directly and 1,031,546 shares held indirectly. Of the indirect amount, 271,546 shares are owned by his wife and 760,000 shares are controlled by him as co‑trustee of the Alfred R. Globus Testamentary Trust, which is treated as beneficially owned due to his voting authority.
United-Guardian (UG) filed its Q3 2025 10-Q reporting lower sales and earnings. Net sales were $2,264,261, down from $3,060,113 a year ago, with nine‑month sales at $7,583,613 versus $9,705,262. Net income was $268,441 in the quarter (vs. $865,484) and $1,456,162 year‑to‑date (vs. $2,747,151). EPS was $0.06 for the quarter (vs. $0.19) and $0.32 year‑to‑date (vs. $0.60).
Mix and volume pressures weighed on margins: cost of sales rose to 58% of sales in Q3 (46% prior year) and to 50% for the nine months (47% prior year), reflecting a higher contribution from lower‑margin pharmaceuticals and lower cosmetic volumes. Cosmetic ingredient sales softened, particularly tied to China demand and tariff dynamics, while pharmaceuticals grew on both a gross and net basis.
Operating cash flow was $1,636,324 for the nine months. The company paid cash dividends of $0.35 per share in February and $0.25 per share in August. Management highlighted ongoing tariff uncertainty related to China and noted the Natrajel launch timing has shifted to 2026 due to customer timelines. Working capital remains strong with a 7.0:1 current ratio.